GlassScriptPhysician profile
Suneil K Aggarwal
NPI 1396152328
$1,142.96
in general payments reported to CMS, 2019-2025
20 companies · $189 in 2025
The $189 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $372 · 2020: $69.77 · 2021: $193 · 2022: $120 · 2023: $128 · 2024: $71.95 · 2025: $189.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $389.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $388.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $187.43 | 2019-2024 | Camzyos, Eliquis |
| Gilead Sciences, INC. | $126.52 | 2021-2023 | |
| Ucb, INC. | $87.44 | 2021-2025 | Briviact |
| Melinta Therapeutics, LLC | $83.24 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $76.85 | 2019-2023 | Stiolto Respimat, Spiriva Respimat |
| Novo Nordisk INC | $76.78 | 2019-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $62.14 | 2025 | |
| Novartis Pharmaceuticals Corporation | $61.58 | 2019 | |
| Merck Sharp & Dohme LLC | $57.54 | 2019-2025 | Zerbaxa |
| Janssen Pharmaceuticals, INC | $55.36 | 2019-2022 | |
| Abbvie INC. | $51.99 | 2021-2023 | Teflaro |
| La Jolla Pharmaceutical Company | $44.35 | 2023-2024 | Xerava |
| Boston Scientific Corporation | $41.63 | 2020-2025 | Watchman Flx |
| Paratek Pharmaceuticals, INC. | $26.72 | 2020-2022 | |
| Philips North America LLC | $22.29 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $20.75 | 2024 | |
| Kiniksa Pharmaceuticals, LTD. | $17.13 | 2023 | Arcalyst |
| Advanced Respiratory, INC | $15.59 | 2019 | |
| Alnylam Pharmaceuticals INC. | $15.00 | 2024 | Givlaari |
| Allergan, INC. | $12.63 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suneil Aggarwal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.